{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:09:07Z","timestamp":1791288547733,"version":"4.3.0"},"reference-count":174,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T00:00:00Z","timestamp":1708905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH","award":["T32 CA009666"],"award-info":[{"award-number":["T32 CA009666"]}]},{"name":"Fondation pour la Recherche Medicale","award":["T32 CA009666"],"award-info":[{"award-number":["T32 CA009666"]}]},{"name":"Fondation Nuovo-Soldati","award":["T32 CA009666"],"award-info":[{"award-number":["T32 CA009666"]}]},{"name":"LMS SPORE Career Enhancement Program","award":["T32 CA009666"],"award-info":[{"award-number":["T32 CA009666"]}]},{"name":"QuadW Foundation","award":["T32 CA009666"],"award-info":[{"award-number":["T32 CA009666"]}]},{"name":"Sarcoma Foundation of America","award":["T32 CA009666"],"award-info":[{"award-number":["T32 CA009666"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Leiomyosarcoma (LMS) is an aggressive subtype of soft tissue sarcoma that arises from smooth muscle cells, most commonly in the uterus and retroperitoneum. LMS is a heterogeneous disease with diverse clinical and molecular characteristics that have yet to be fully understood. Molecular profiling has uncovered possible targets amenable to treatment, though this has yet to translate into approved targeted therapies in LMS. This review will explore historic and recent findings from molecular profiling, highlight promising avenues of current investigation, and suggest possible future strategies to move toward the goal of molecularly matched treatment of LMS. We focus on targeting the DNA damage response, the macrophage-rich micro-environment, the PI3K\/mTOR pathway, epigenetic regulators, and telomere biology.<\/jats:p>","DOI":"10.3390\/cancers16050938","type":"journal-article","created":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T11:31:21Z","timestamp":1708947081000},"page":"938","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The Future of Targeted Therapy for Leiomyosarcoma"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9698-9201","authenticated-orcid":false,"given":"Ryan A.","family":"Denu","sequence":"first","affiliation":[{"name":"Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda M.","family":"Dann","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Department of Surgery, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily Z.","family":"Keung","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Nakazawa","sequence":"additional","affiliation":[{"name":"Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3794-6759","authenticated-orcid":false,"given":"Elise F.","family":"Nassif Haddad","sequence":"additional","affiliation":[{"name":"Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/00000478-200201000-00002","article-title":"Leiomyosarcoma of Somatic Soft Tissues: A Tumor of Vascular Origin with Multivariate Analysis of Outcome in 42 Cases","volume":"26","author":"Farshid","year":"2002","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1245\/s10434-013-2876-y","article-title":"Predictors of Survival and Recurrence in Primary Leiomyosarcoma","volume":"20","author":"Gladdy","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/ijgo.12613","article-title":"Uterine Sarcomas","volume":"143","author":"Mbatani","year":"2018","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/1097-0142(19920701)70:1<114::AID-CNCR2820700119>3.0.CO;2-U","article-title":"Soft Tissue Leiomyosarcoma. A Population-Based Epidemiologic and Prognostic Study of 48 Patients, Including Cellular DNA Content","volume":"70","author":"Gustafson","year":"1992","journal-title":"Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1002\/ijc.22239","article-title":"Incidence Patterns of Soft Tissue Sarcomas, Regardless of Primary Site, in the Surveillance, Epidemiology and End Results Program, 1978\u20132001: An Analysis of 26,758 Cases","volume":"119","author":"Toro","year":"2006","journal-title":"Int. J. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Cope, B.M., Traweek, R.S., Lazcano, R., Keung, E.Z., Lazar, A.J., Roland, C.L., and Nassif, E.F. (2023). Targeting the Molecular and Immunologic Features of Leiomyosarcoma. Cancers, 15.","DOI":"10.3390\/cancers15072099"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S1470-2045(22)00380-1","article-title":"Doxorubicin Alone versus Doxorubicin with Trabectedin Followed by Trabectedin Alone as First-Line Therapy for Metastatic or Unresectable Leiomyosarcoma (LMS-04): A Randomised, Multicentre, Open-Label Phase 3 Trial","volume":"23","author":"Pautier","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","article-title":"Doxorubicin Alone versus Intensified Doxorubicin plus Ifosfamide for First-Line Treatment of Advanced or Metastatic Soft-Tissue Sarcoma: A Randomised Controlled Phase 3 Trial","volume":"15","author":"Judson","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2006.10.4117","article-title":"Randomized Phase II Study of Gemcitabine and Docetaxel Compared with Gemcitabine Alone in Patients with Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research through Collaboration Study 002 [Corrected]","volume":"25","author":"Maki","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1200\/JCO.2002.11.050","article-title":"Gemcitabine and Docetaxel in Patients with Unresectable Leiomyosarcoma: Results of a Phase II Trial","volume":"20","author":"Hensley","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1200\/JCO.2001.19.15.3483","article-title":"Phase II Clinical Investigation of Gemcitabine in Advanced Soft Tissue Sarcomas and Window Evaluation of Dose Rate on Gemcitabine Triphosphate Accumulation","volume":"19","author":"Patel","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1200\/JCO.2000.18.10.2081","article-title":"Randomized Phase II Study of Docetaxel versus Doxorubicin in First- and Second-Line Chemotherapy for Locally Advanced or Metastatic Soft Tissue Sarcomas in Adults: A Study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group","volume":"18","author":"Verweij","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00428-009-0853-4","article-title":"Soft Tissue Sarcomas with Complex Genomic Profiles","volume":"456","author":"Guillou","year":"2010","journal-title":"Virchows Arch."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s12094-007-0027-2","article-title":"Molecular Pathology in Sarcomas","volume":"9","year":"2007","journal-title":"Clin. Transl. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2008.06.013","article-title":"Genetic Aberrations in Soft Tissue Leiomyosarcoma","volume":"275","author":"Yang","year":"2009","journal-title":"Cancer Lett."},{"key":"ref_16","unstructured":"Cancer Genome Atlas Research Network, and Cancer Genome Atlas Research Network (2017). Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cell, 171, 950\u2013965.e28."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/gcc.22318","article-title":"Targeted Exome Sequencing Profiles Genetic Alterations in Leiomyosarcoma","volume":"55","author":"Agaram","year":"2016","journal-title":"Genes. Chromosomes Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"12234","DOI":"10.18632\/oncotarget.3498","article-title":"Multi-Platform Profiling of over 2000 Sarcomas: Identification of Biomarkers and Novel Therapeutic Targets","volume":"6","author":"Movva","year":"2015","journal-title":"Oncotarget"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/ijc.31129","article-title":"Integrated Genome Analysis of Uterine Leiomyosarcoma to Identify Novel Driver Genes and Targetable Pathways","volume":"142","author":"Cuppens","year":"2018","journal-title":"Int. J. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41467-017-02602-0","article-title":"Integrative Genomic and Transcriptomic Analysis of Leiomyosarcoma","volume":"9","author":"Chudasama","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"M\u00e4kinen, N., Aavikko, M., Heikkinen, T., Taipale, M., Taipale, J., Koivisto-Korander, R., B\u00fctzow, R., and Vahteristo, P. (2016). Exome Sequencing of Uterine Leiomyosarcomas Identifies Frequent Mutations in TP53, ATRX, and MED12. PLoS Genet., 12.","DOI":"10.1371\/journal.pgen.1005850"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.yexmp.2017.01.012","article-title":"Spectrum of Mutations in Leiomyosarcomas Identified by Clinical Targeted Next-Generation Sequencing","volume":"102","author":"Lee","year":"2017","journal-title":"Exp. Mol. Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-19-3959","article-title":"Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing","volume":"26","author":"Hensley","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.1038\/s41467-021-24677-6","article-title":"Lineage-Defined Leiomyosarcoma Subtypes Emerge Years before Diagnosis and Determine Patient Survival","volume":"12","author":"Anderson","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.cancergencyto.2005.01.011","article-title":"Loss of DNA Copy Number of 10q Is Associated with Aggressive Behavior of Leiomyosarcomas: A Comparative Genomic Hybridization Study","volume":"161","author":"Hu","year":"2005","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.cancergencyto.2006.01.008","article-title":"Gene Copy Number Profiling of Soft-Tissue Leiomyosarcomas by Array-Comparative Genomic Hybridization","volume":"169","author":"Larramendy","year":"2006","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0002-9440(10)65640-4","article-title":"DNA Copy Number Changes in Development and Progression in Leiomyosarcomas of Soft Tissues","volume":"153","author":"Knuutila","year":"1998","journal-title":"Am. J. Pathol."},{"key":"ref_28","first-page":"207","article-title":"Analysis of chromosome copy number changes in leiomyosarcoma through molecular cytogenetic methods","volume":"82","author":"Mechtersheimer","year":"1998","journal-title":"Verh. Dtsch. Ges. Pathol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0165-4608(99)00082-5","article-title":"Comparative Genomic Hybridization Reveals Novel Chromosome Deletions in 90 Primary Soft Tissue Tumors","volume":"115","author":"Parente","year":"1999","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JCO.2017.75.9845","article-title":"Soft Tissue and Uterine Leiomyosarcoma","volume":"36","author":"George","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cell.2010.11.055","article-title":"Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development","volume":"144","author":"Stephens","year":"2011","journal-title":"Cell"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1091\/mbc.12.5.1315","article-title":"Tetraploid State Induces P53-Dependent Arrest of Nontransformed Mammalian Cells in G1","volume":"12","author":"Andreassen","year":"2001","journal-title":"Mol. Biol. Cell"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrm1276","article-title":"From Polyploidy to Aneuploidy, Genome Instability and Cancer","volume":"5","author":"Storchova","year":"2004","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1242\/jcs.039537","article-title":"The Consequences of Tetraploidy and Aneuploidy","volume":"121","author":"Storchova","year":"2008","journal-title":"J. Cell Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1038\/s41467-022-30496-0","article-title":"Clinical Genomic Profiling in the Management of Patients with Soft Tissue and Bone Sarcoma","volume":"13","author":"Gounder","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1038\/s41467-022-30453-x","article-title":"Clinical Sequencing of Soft Tissue and Bone Sarcomas Delineates Diverse Genomic Landscapes and Potential Therapeutic Targets","volume":"13","author":"Nacev","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"AACR Project GENIE Consortium (2017). AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov., 7, 818\u2013831.","DOI":"10.1158\/2159-8290.CD-17-0151"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1158\/2159-8290.CD-21-1547","article-title":"AACR Project GENIE: 100,000 Cases and Beyond","volume":"12","author":"Pugh","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Francis, P., Naml\u00f8s, H.M., M\u00fcller, C., Ed\u00e9n, P., Fernebro, J., Berner, J.-M., Bjerkehagen, B., Akerman, M., Bendahl, P.-O., and Isinger, A. (2007). Diagnostic and Prognostic Gene Expression Signatures in 177 Soft Tissue Sarcomas: Hypoxia-Induced Transcription Profile Signifies Metastatic Potential. BMC Genom., 8.","DOI":"10.1186\/1471-2164-8-73"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/onc.2009.381","article-title":"Discovery of Molecular Subtypes in Leiomyosarcoma through Integrative Molecular Profiling","volume":"29","author":"Beck","year":"2010","journal-title":"Oncogene"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"9226","DOI":"10.1158\/0008-5472.CAN-05-1699","article-title":"Gene Expression Profiling of Human Sarcomas: Insights into Sarcoma Biology","volume":"65","author":"Baird","year":"2005","journal-title":"Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1158\/1078-0432.CCR-14-3141","article-title":"Clinically Relevant Molecular Subtypes in Leiomyosarcoma","volume":"21","author":"Guo","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.critrevonc.2010.02.012","article-title":"Pazopanib: Clinical Development of a Potent Anti-Angiogenic Drug","volume":"77","author":"Schutz","year":"2011","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for Metastatic Soft-Tissue Sarcoma (PALETTE): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial","volume":"379","author":"Blay","year":"2012","journal-title":"Lancet"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ygyno.2016.03.024","article-title":"Outcome of Uterine Sarcoma Patients Treated with Pazopanib: A Retrospective Analysis Based on Two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) Clinical Trials 62043 and 62072","volume":"142","author":"Benson","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","article-title":"FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-Agnostic Efficacy and Safety of Selpercatinib in Patients with RET Fusion-Positive Solid Tumours Other than Lung or Thyroid Tumours (LIBRETTO-001): A Phase 1\/2, Open-Label, Basket Trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1158\/1078-0432.CCR-20-2771","article-title":"FDA Approval Summary: Entrectinib for the Treatment of NTRK Gene Fusion Solid Tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/2045-3329-4-5","article-title":"Treatment of Hormone Positive Uterine Leiomyosarcoma with Aromatase Inhibitors","volume":"4","author":"Thanopoulou","year":"2014","journal-title":"Clin. Sarcoma Res."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Maccaroni, E., Lunerti, V., Agostinelli, V., Giampieri, R., Zepponi, L., Pagliacci, A., and Berardi, R. (2022). New Insights into Hormonal Therapies in Uterine Sarcomas. Cancers, 14.","DOI":"10.3390\/cancers14040921"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/cam4.2044","article-title":"Hormonal Therapy in Uterine Sarcomas","volume":"8","author":"Zang","year":"2019","journal-title":"Cancer Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/ajcp\/aqw030","article-title":"Progesterone Receptor Expression Is an Independent Prognosticator in FIGO Stage I Uterine Leiomyosarcoma","volume":"145","author":"Davidson","year":"2016","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ygyno.2005.05.019","article-title":"The Expression of Ki-67, P53, Estrogen and Progesterone Receptors Affecting Survival in Uterine Leiomyosarcomas. A Clinicopathologic Study","volume":"99","author":"Akhan","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"ref_55","first-page":"729","article-title":"Estrogen and Progesterone Receptor Expression in Patients with Uterine Leiomyosarcoma and Correlation with Different Clinicopathological Parameters","volume":"23","author":"Bodner","year":"2003","journal-title":"Anticancer. Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jsbmb.2003.11.013","article-title":"Aromatase Cytochrome P450 and Estrogen and Progesterone Receptors in Uterine Sarcomas: Correlation with Clinical Parameters","volume":"88","author":"Kitaoka","year":"2004","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ygyno.2011.11.009","article-title":"Immunohistochemical Expression of Estrogen and Progesterone Receptors and Outcomes in Patients with Newly Diagnosed Uterine Leiomyosarcoma","volume":"124","author":"Leitao","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ygyno.2009.08.014","article-title":"Hormone Receptor Expression in Uterine Sarcomas: Prognostic and Therapeutic Roles","volume":"115","author":"Ioffe","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/cncr.28476","article-title":"Phase 2 Trial of Aromatase Inhibition with Letrozole in Patients with Uterine Leiomyosarcomas Expressing Estrogen and\/or Progesterone Receptors","volume":"120","author":"George","year":"2014","journal-title":"Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1158\/1078-0432.CCR-23-0692","article-title":"Low-Grade Uterine Leiomyosarcoma Is Highly Sensitive to Hormonal Treatment","volume":"29","author":"Sanfilippo","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/bjc.2017.187","article-title":"Human Equilibrative Nucleoside Transporter 1 Gene Expression Is Associated with Gemcitabine Efficacy in Advanced Leiomyosarcoma and Angiosarcoma","volume":"117","author":"Vincenzi","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.ejca.2011.01.016","article-title":"Predictive Impact of DNA Repair Functionality on Clinical Outcome of Advanced Sarcoma Patients Treated with Trabectedin: A Retrospective Multicentric Study","volume":"47","author":"Taron","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0092-8674(02)00615-3","article-title":"Cancer Susceptibility and the Functions of BRCA1 and BRCA2","volume":"108","author":"Venkitaraman","year":"2002","journal-title":"Cell"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S1097-2765(00)80202-6","article-title":"Brca1 Controls Homology-Directed DNA Repair","volume":"4","author":"Moynahan","year":"1999","journal-title":"Mol. Cell"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA Repair Defect in BRCA Mutant Cells as a Therapeutic Strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific Killing of BRCA2-Deficient Tumours with Inhibitors of Poly(ADP-Ribose) Polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13046-016-0456-2","article-title":"Use of Poly ADP-Ribose Polymerase [PARP] Inhibitors in Cancer Cells Bearing DDR Defects: The Rationale for Their Inclusion in the Clinic","volume":"35","author":"Cerrato","year":"2016","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.molonc.2011.07.001","article-title":"The Underlying Mechanism for the PARP and BRCA Synthetic Lethality: Clearing up the Misunderstandings","volume":"5","author":"Helleday","year":"2011","journal-title":"Mol. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1158\/1078-0432.CCR-16-2520","article-title":"DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma","volume":"23","author":"Teo","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"6204","DOI":"10.1158\/1078-0432.CCR-18-1472","article-title":"Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX","volume":"24","author":"Sehdev","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1634\/theoncologist.2018-0448","article-title":"BRCA1\/2 Functional Loss Defines a Targetable Subset in Leiomyosarcoma","volume":"24","author":"Seligson","year":"2019","journal-title":"Oncologist"},{"key":"ref_72","first-page":"PO.20.00122","article-title":"Clinical Outcome of Leiomyosarcomas with Somatic Alteration in Homologous Recombination Pathway Genes","volume":"4","author":"Rosenbaum","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13046-023-02687-0","article-title":"Targeting Homologous Recombination Deficiency in Uterine Leiomyosarcoma","volume":"42","author":"Dall","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/s41416-020-1016-2","article-title":"Complete Loss of ATM Function Augments Replication Catastrophe Induced by ATR Inhibition and Gemcitabine in Pancreatic Cancer Models","volume":"123","author":"Dunlop","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1146\/annurev.micro.57.030502.090847","article-title":"DNA Mismatch Repair: Molecular Mechanisms and Biological Function","volume":"57","author":"Schofield","year":"2003","journal-title":"Annu. Rev. Microbiol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10689-008-9230-8","article-title":"Sarcomas Associated with Hereditary Nonpolyposis Colorectal Cancer: Broad Anatomical and Morphological Spectrum","volume":"8","author":"Nilbert","year":"2009","journal-title":"Fam. Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/s41379-019-0202-3","article-title":"Characteristics of Mismatch Repair Deficiency in Sarcomas","volume":"32","author":"Doyle","year":"2019","journal-title":"Mod. Pathol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/S1470-2045(18)30438-8","article-title":"Trabectedin and Olaparib in Patients with Advanced and Non-Resectable Bone and Soft-Tissue Sarcomas (TOMAS): An Open-Label, Phase 1b Study from the Italian Sarcoma Group","volume":"19","author":"Grignani","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_79","first-page":"S1281","article-title":"TOMAS2: A Randomized Phase 2 Study from the Italian Sarcoma Group (ISG) of Trabectedin plus Olaparib (T+O) or Trabectedin (T) in Advanced, Metastatic, or Unresectable Soft Tissue Sarcomas (STS) after Failure of Standard Treatments","volume":"34","author":"Merlini","year":"2023","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1200\/JCO.23.00402","article-title":"Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250)","volume":"41","author":"Ingham","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3389\/fonc.2020.00570","article-title":"Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors","volume":"10","author":"Vikas","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jamaoncol.2022.5228","article-title":"Avelumab Plus Talazoparib in Patients with Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial","volume":"9","author":"Yap","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"11522","DOI":"10.1200\/JCO.2021.39.15_suppl.11522","article-title":"A Phase II, Open-Label, Randomized Trial of Durvalumab (D) with Olaparib (O) or Cediranib (C) in Patients (Pts) with Leiomyosarcoma (LMS)","volume":"39","author":"Ayodele","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ctrv.2003.07.007","article-title":"PI3K\/Akt Signalling Pathway and Cancer","volume":"30","author":"Casado","year":"2004","journal-title":"Cancer Treat. Rev."},{"key":"ref_85","first-page":"5808","article-title":"PTEN Suppresses Breast Cancer Cell Growth by Phosphatase Activity-Dependent G1 Arrest Followed by Cell Death","volume":"59","author":"Weng","year":"1999","journal-title":"Cancer Res."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Zou, Z., Tao, T., Li, H., and Zhu, X. (2020). mTOR Signaling Pathway and mTOR Inhibitors in Cancer: Progress and Challenges. Cell Biosci., 10.","DOI":"10.1186\/s13578-020-00396-1"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/path.2787","article-title":"New Insights in Sarcoma Oncogenesis: A Comprehensive Analysis of a Large Series of 160 Soft Tissue Sarcomas with Complex Genomics","volume":"223","author":"Gibault","year":"2011","journal-title":"J. Pathol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/modpathol.2011.163","article-title":"From PTEN Loss of Expression to RICTOR Role in Smooth Muscle Differentiation: Complex Involvement of the mTOR Pathway in Leiomyosarcomas and Pleomorphic Sarcomas","volume":"25","author":"Gibault","year":"2012","journal-title":"Mod. Pathol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1634\/theoncologist.2017-0290","article-title":"Next-Generation Sequencing for Patients with Sarcoma: A Single Center Experience","volume":"23","author":"Cote","year":"2018","journal-title":"Oncologist"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nm1560","article-title":"The AKT-mTOR Pathway Plays a Critical Role in the Development of Leiomyosarcomas","volume":"13","author":"Hernando","year":"2007","journal-title":"Nat. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s12032-015-0554-6","article-title":"PI3K\/AKT\/mTOR Pathway Is Activated after Imatinib Secondary Resistance in Gastrointestinal Stromal Tumors (GISTs)","volume":"32","author":"Li","year":"2015","journal-title":"Med. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.immuni.2017.02.001","article-title":"Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma","volume":"46","author":"George","year":"2017","journal-title":"Immunity"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","article-title":"Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy","volume":"6","author":"Peng","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s12935-022-02706-8","article-title":"Recent Advances and Limitations of mTOR Inhibitors in the Treatment of Cancer","volume":"22","author":"Ali","year":"2022","journal-title":"Cancer Cell Int."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1200\/JCO.2012.45.5766","article-title":"Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus versus Placebo to Control Metastatic Sarcomas in Patients after Benefit from Prior Chemotherapy","volume":"31","author":"Demetri","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/sj.onc.1209990","article-title":"Rapamycin Induces Feedback Activation of Akt Signaling through an IGF-1R-Dependent Mechanism","volume":"26","author":"Wan","year":"2007","journal-title":"Oncogene"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"7878","DOI":"10.18632\/oncotarget.13987","article-title":"Dual Inhibition of the PI3K\/AKT\/mTOR Pathway Suppresses the Growth of Leiomyosarcomas but Leads to ERK Activation through mTORC2: Biological and Clinical Implications","volume":"8","author":"Fourneaux","year":"2017","journal-title":"Oncotarget"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Mendes-Pereira, A.M., Lord, C.J., and Ashworth, A. (2012). NLK Is a Novel Therapeutic Target for PTEN Deficient Tumour Cells. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0047249"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e1386828","DOI":"10.1080\/2162402X.2017.1386828","article-title":"Increased Infiltration of M2-Macrophages, T-Cells and PD-L1 Expression in High Grade Leiomyosarcomas Supports Immunotherapeutic Strategies","volume":"7","author":"Kostine","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1471-4906(02)02302-5","article-title":"Macrophage Polarization: Tumor-Associated Macrophages as a Paradigm for Polarized M2 Mononuclear Phagocytes","volume":"23","author":"Mantovani","year":"2002","journal-title":"Trends Immunol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1158\/1078-0432.CCR-07-1712","article-title":"Prognostic Significance of Macrophage Infiltration in Leiomyosarcomas","volume":"14","author":"Lee","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1002\/cncr.30738","article-title":"Immunotherapy with Single Agent Nivolumab for Advanced Leiomyosarcoma of the Uterus: Results of a Phase 2 Study","volume":"123","author":"Barysauskas","year":"2017","journal-title":"Cancer"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in Advanced Soft-Tissue Sarcoma and Bone Sarcoma (SARC028): A Multicentre, Two-Cohort, Single-Arm, Open-Label, Phase 2 Trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(18)30006-8","article-title":"Nivolumab with or without Ipilimumab Treatment for Metastatic Sarcoma (Alliance A091401): Two Open-Label, Non-Comparative, Randomised, Phase 2 Trials","volume":"19","author":"Mahoney","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"S1032","DOI":"10.1016\/j.annonc.2023.09.1148","article-title":"Efficacy and Safety of Botensilimab plus Balstilimab in Patients with Refractory Metastatic Sarcoma","volume":"34","author":"Wilky","year":"2023","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"S1114","DOI":"10.1016\/j.annonc.2021.08.856","article-title":"1526MO GEMMK: A Phase I Study of Gemcitabine (Gem) and Pembrolizumab (Pem) in Patients (Pts) with Leiomyosarcoma (LMS) and Undifferentiated Pleomorphic Sarcoma UPS)","volume":"32","author":"Smrke","year":"2021","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_107","unstructured":"Napolitano, A. (2022, January 16\u201319). Final Results of GEMMK: A Phase I Trial of Gemcitabine and Pembrolizumab in Patients with Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma. Proceedings of the CTOS Annual Meeting, Vancouver, BC, Canada."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"11559","DOI":"10.1200\/JCO.2020.38.15_suppl.11559","article-title":"Phase II Study of Eribulin and Pembrolizumab in Patients (Pts) with Metastatic Soft Tissue Sarcomas (STS): Report of LMS Cohort","volume":"38","author":"Nathenson","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"11502","DOI":"10.1200\/JCO.2023.41.16_suppl.11502","article-title":"ImmunoSarc2: A Spanish Sarcoma Group (GEIS) Phase Ib Trial of Doxorubicin and Dacarbazine plus Nivolumab in First Line Treatment of Advanced Leiomyosarcoma","volume":"41","author":"Moura","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"11518","DOI":"10.1200\/JCO.2023.41.16_suppl.11518","article-title":"Interim Results of a Phase II Trial of First Line Retifanlimab (R) plus Gemcitabine and Docetaxel (GD) in Patients (Pts) with Advanced Soft Tissue Sarcoma (STS)","volume":"41","author":"Rosenbaum","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"11500","DOI":"10.1200\/JCO.2023.41.16_suppl.11500","article-title":"Efficacy and Safety of Nivolumab and Trabectedin in Pretreated Patients with Advanced Soft Tissue Sarcomas (STS): Results of a Phase II Trial of the German Interdisciplinary Sarcoma Group (GISG-15, NitraSarc)","volume":"41","author":"Reichardt","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"11501","DOI":"10.1200\/JCO.2023.41.16_suppl.11501","article-title":"A Single-Arm, Open-Label Phase 2 Trial of Doxorubicin plus Zalifrelimab, a CTLA-4 Inhibitor, with Balstilimab, a PD-1 Inhibitor, in Patients with Advanced\/Metastatic Soft Tissue Sarcomas","volume":"41","author":"Wilky","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1470-2045(19)30153-6","article-title":"Axitinib plus Pembrolizumab in Patients with Advanced Sarcomas Including Alveolar Soft-Part Sarcoma: A Single-Centre, Single-Arm, Phase 2 Trial","volume":"20","author":"Wilky","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"11517","DOI":"10.1200\/JCO.2023.41.16_suppl.11517","article-title":"A Pilot Study of Lenvatinib plus Pembrolizumab in Patients with Advanced Sarcoma","volume":"41","author":"Movva","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"LBA11504","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA11504","article-title":"Randomized Phase II Trial of Cabozantinib Combined with PD-1 and CTLA-4 Inhibition versus Cabozantinib in Metastatic Soft Tissue Sarcoma","volume":"41","author":"Eulo","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1158\/2159-8290.CD-20-0522","article-title":"Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors","volume":"10","author":"Sha","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 Human Cancer Genomes Reveals the Landscape of Tumor Mutational Burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0962-8924(00)01906-1","article-title":"Integrin-Associated Protein (CD47) and Its Ligands","volume":"11","author":"Brown","year":"2001","journal-title":"Trends Cell Biol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1073\/pnas.1121629109","article-title":"Antibody Therapy Targeting the CD47 Protein Is Effective in a Model of Aggressive Metastatic Leiomyosarcoma","volume":"109","author":"Edris","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"TPS11593","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS11593","article-title":"TTI-621-03: A Phase I\/II Study of TTI-621 in Combination with Doxorubicin in Patients with Unresectable or Metastatic High-Grade Leiomyosarcoma (LMS)","volume":"40","author":"Sant","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"11508","DOI":"10.1200\/JCO.2023.41.16_suppl.11508","article-title":"Safety and Clinical Activity of TTI-621 in Combination with Doxorubicin in Patients with Unresectable or Metastatic High-Grade Leiomyosarcoma: Results from the Low-Dose Expansion Cohort","volume":"41","author":"Movva","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.2353\/ajpath.2009.081037","article-title":"Coordinate Expression of Colony-Stimulating Factor-1 and Colony-Stimulating Factor-1-Related Proteins Is Associated with Poor Prognosis in Gynecological and Nongynecological Leiomyosarcoma","volume":"174","author":"Espinosa","year":"2009","journal-title":"Am. J. Pathol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"12007","DOI":"10.1038\/s41598-022-16080-y","article-title":"GM-CSF Derived from the Inflammatory Microenvironment Potentially Enhanced PD-L1 Expression on Tumor-Associated Macrophages in Human Breast Cancer","volume":"12","author":"Yonemitsu","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e004076","DOI":"10.1136\/jitc-2021-004076","article-title":"Anti-CSF-1R Emactuzumab in Combination with Anti-PD-L1 Atezolizumab in Advanced Solid Tumor Patients Na\u00efve or Experienced for Immune Checkpoint Blockade","volume":"10","author":"Cassier","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1199631","DOI":"10.3389\/fimmu.2023.1199631","article-title":"Targeting Immune Checkpoints on Tumor-Associated Macrophages in Tumor Immunotherapy","volume":"14","author":"Xu","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"e02172","DOI":"10.7554\/eLife.02172","article-title":"Immunosuppression via Adenosine Receptor Activation by Adenosine Monophosphate Released from Apoptotic Cells","volume":"3","author":"Yamaguchi","year":"2014","journal-title":"eLife"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.3389\/fimmu.2019.02759","article-title":"More Than Just Attractive: How CCL2 Influences Myeloid Cell Behavior Beyond Chemotaxis","volume":"10","author":"Gschwandtner","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0952-7915(98)80172-6","article-title":"Mammalian Target of Rapamycin: Immunosuppressive Drugs Uncover a Novel Pathway of Cytokine Receptor Signaling","volume":"10","author":"Abraham","year":"1998","journal-title":"Curr. Opin. Immunol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"7797","DOI":"10.1073\/pnas.0800928105","article-title":"T Cell Receptor Signaling Controls Foxp3 Expression via PI3K, Akt, and mTOR","volume":"105","author":"Sauer","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nature07091","article-title":"Essential Roles of PI(3)K-P110beta in Cell Growth, Metabolism and Tumorigenesis","volume":"454","author":"Jia","year":"2008","journal-title":"Nature"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41392-021-00506-6","article-title":"Targeting Macrophages in Cancer Immunotherapy","volume":"6","author":"Duan","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","article-title":"Macrophages as Regulators of Tumour Immunity and Immunotherapy","volume":"19","author":"DeNardo","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/s41568-020-0288-4","article-title":"The Epigenomics of Sarcoma","volume":"20","author":"Nacev","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"e2025182118","DOI":"10.1073\/pnas.2025182118","article-title":"Integrated Mutational Landscape Analysis of Uterine Leiomyosarcomas","volume":"118","author":"Choi","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.celrep.2015.03.036","article-title":"ATRX Plays a Key Role in Maintaining Silencing at Interstitial Heterochromatic Loci and Imprinted Genes","volume":"11","author":"Voon","year":"2015","journal-title":"Cell Rep."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nsmb.2062","article-title":"ATRX ADD Domain Links an Atypical Histone Methylation Recognition Mechanism to Human Mental-Retardation Syndrome","volume":"18","author":"Iwase","year":"2011","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.cell.2011.04.015","article-title":"DNA Replication through G-Quadruplex Motifs Is Promoted by the Saccharomyces Cerevisiae Pif1 DNA Helicase","volume":"145","author":"Paeschke","year":"2011","journal-title":"Cell"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"101147","DOI":"10.1016\/j.tranon.2021.101147","article-title":"Loss of ATRX Confers DNA Repair Defects and PARP Inhibitor Sensitivity","volume":"14","author":"Garbarino","year":"2021","journal-title":"Transl. Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"e149310","DOI":"10.1172\/JCI149310","article-title":"Atrx Deletion Impairs CGAS\/STING Signaling and Increases Sarcoma Response to Radiation and Oncolytic Herpesvirus","volume":"133","author":"Floyd","year":"2023","journal-title":"J. Clin. Investig."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Darmusey, L., P\u00e9rot, G., Th\u00e9bault, N., Le Guellec, S., Desplat, N., Gaston, L., Delespaul, L., Lesluyes, T., Darbo, E., and Gomez-Brouchet, A. (2021). ATRX Alteration Contributes to Tumor Growth and Immune Escape in Pleomorphic Sarcomas. Cancers, 13.","DOI":"10.3390\/cancers13092151"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1126\/science.1208930","article-title":"MED12, the Mediator Complex Subunit 12 Gene, Is Mutated at High Frequency in Uterine Leiomyomas","volume":"334","author":"Mehine","year":"2011","journal-title":"Science"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1172\/JCI81534","article-title":"Med12 Gain-of-Function Mutation Causes Leiomyomas and Genomic Instability","volume":"125","author":"Mittal","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"P\u00e9rot, G., Croce, S., Ribeiro, A., Lagarde, P., Velasco, V., Neuville, A., Coindre, J.-M., Stoeckle, E., Floquet, A., and MacGrogan, G. (2012). MED12 Alterations in Both Human Benign and Malignant Uterine Soft Tissue Tumors. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0040015"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"4870","DOI":"10.1074\/jbc.RA118.001725","article-title":"Oncogenic Exon 2 Mutations in Mediator Subunit MED12 Disrupt Allosteric Activation of Cyclin C-CDK8\/19","volume":"293","author":"Park","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.celrep.2014.03.047","article-title":"Uterine Leiomyoma-Linked MED12 Mutations Disrupt Mediator-Associated CDK Activity","volume":"7","author":"Turunen","year":"2014","journal-title":"Cell Rep."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"153920","DOI":"10.1016\/j.prp.2022.153920","article-title":"Cyclin-Dependent Kinase 8 Is an Independent Prognosticator in Uterine Leiomyosarcoma","volume":"235","author":"Yasutake","year":"2022","journal-title":"Pathol. Res. Pract."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.1038\/s41467-023-39684-y","article-title":"Engineered MED12 Mutations Drive Leiomyoma-like Transcriptional and Metabolic Programs by Altering the 3D Genome Compartmentalization","volume":"14","author":"Buyukcelebi","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"6169","DOI":"10.1038\/s41598-022-10188-x","article-title":"Aberrant R-Loop-Induced Replication Stress in MED12-Mutant Uterine Fibroids","volume":"12","author":"Muralimanoharan","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1128\/MCB.23.7.2425-2437.2003","article-title":"Myocardin Is a Critical Serum Response Factor Cofactor in the Transcriptional Program Regulating Smooth Muscle Cell Differentiation","volume":"23","author":"Du","year":"2003","journal-title":"Mol. Cell Biol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"7129","DOI":"10.1073\/pnas.1232341100","article-title":"Myocardin Is a Master Regulator of Smooth Muscle Gene Expression","volume":"100","author":"Wang","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nature02382","article-title":"Myocardin and Ternary Complex Factors Compete for SRF to Control Smooth Muscle Gene Expression","volume":"428","author":"Wang","year":"2004","journal-title":"Nature"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1158\/0008-5472.CAN-08-1443","article-title":"Strong Smooth Muscle Differentiation Is Dependent on Myocardin Gene Amplification in Most Human Retroperitoneal Leiomyosarcomas","volume":"69","author":"Coindre","year":"2009","journal-title":"Cancer Res."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"6091","DOI":"10.1128\/MCB.21.18.6091-6101.2001","article-title":"The SMRT and N-CoR Corepressors Are Activating Cofactors for Histone Deacetylase 3","volume":"21","author":"Guenther","year":"2001","journal-title":"Mol. Cell Biol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.18632\/oncotarget.28032","article-title":"Epigenetic Signatures Differentiate Uterine and Soft Tissue Leiomyosarcoma","volume":"12","author":"Hasan","year":"2021","journal-title":"Oncotarget"},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Renner, M., Wolf, T., Meyer, H., Hartmann, W., Penzel, R., Ulrich, A., Lehner, B., Hovestadt, V., Czwan, E., and Egerer, G. (2013). Integrative DNA Methylation and Gene Expression Analysis in High-Grade Soft Tissue Sarcomas. Genome Biol., 14.","DOI":"10.1186\/gb-2013-14-12-r137"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41467-020-20603-4","article-title":"Sarcoma Classification by DNA Methylation Profiling","volume":"12","author":"Koelsche","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"11550","DOI":"10.1200\/JCO.2020.38.15_suppl.11550","article-title":"Phase Ib Study of Decitabine in Combination with Gemcitabine in Treatment of Advanced Soft Tissue and Bone Sarcomas","volume":"38","author":"Monga","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/345458a0","article-title":"Telomeres Shorten during Ageing of Human Fibroblasts","volume":"345","author":"Harley","year":"1990","journal-title":"Nature"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.gde.2020.02.006","article-title":"Mechanisms That Drive Telomere Maintenance and Recombination in Human Cancers","volume":"60","author":"Sobinoff","year":"2020","journal-title":"Curr. Opin. Genet. Dev."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1158\/1078-0432.217.11.1","article-title":"A Robust Assay for Alternative Lengthening of Telomeres in Tumors Shows the Significance of Alternative Lengthening of Telomeres in Sarcomas and Astrocytomas","volume":"11","author":"Henson","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_161","first-page":"1759","article-title":"Absence of a Telomere Maintenance Mechanism as a Favorable Prognostic Factor in Patients with Osteosarcoma","volume":"63","author":"Ulaner","year":"2003","journal-title":"Cancer Res."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/PAS.0000000000000324","article-title":"Leiomyosarcoma with Alternative Lengthening of Telomeres Is Associated with Aggressive Histologic Features, Loss of ATRX Expression, and Poor Clinical Outcome","volume":"39","author":"Liau","year":"2015","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1126\/science.1207313","article-title":"Altered Telomeres in Tumors with ATRX and DAXX Mutations","volume":"333","author":"Heaphy","year":"2011","journal-title":"Science"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1038\/onc.2009.238","article-title":"A Gene Expression Signature Classifying Telomerase and ALT Immortalization Reveals an hTERT Regulatory Network and Suggests a Mesenchymal Stem Cell Origin for ALT","volume":"28","author":"Cairney","year":"2009","journal-title":"Oncogene"},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Amorim, J.P., Santos, G., Vinagre, J., and Soares, P. (2016). The Role of ATRX in the Alternative Lengthening of Telomeres (ALT) Phenotype. Genes, 7.","DOI":"10.3390\/genes7090066"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"14075","DOI":"10.1073\/pnas.1008850107","article-title":"Daxx Is an H3.3-Specific Histone Chaperone and Cooperates with ATRX in Replication-Independent Chromatin Assembly at Telomeres","volume":"107","author":"Lewis","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"7538","DOI":"10.1038\/ncomms8538","article-title":"Suppression of the Alternative Lengthening of Telomere Pathway by the Chromatin Remodelling Factor ATRX","volume":"6","author":"Clynes","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/nbt.1587","article-title":"DNA C-Circles Are Specific and Quantifiable Markers of Alternative-Lengthening-of-Telomeres Activity","volume":"27","author":"Henson","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nrg2763","article-title":"Alternative Lengthening of Telomeres: Models, Mechanisms and Implications","volume":"11","author":"Cesare","year":"2010","journal-title":"Nat. Rev. Genet."},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Lawlor, R.T., Veronese, N., Pea, A., Nottegar, A., Smith, L., Pilati, C., Demurtas, J., Fassan, M., Cheng, L., and Luchini, C. (2019). Alternative Lengthening of Telomeres (ALT) Influences Survival in Soft Tissue Sarcomas: A Systematic Review with Meta-Analysis. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5424-8"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/annonc\/mdu550","article-title":"A Randomized Phase II Study of the Telomerase Inhibitor Imetelstat as Maintenance Therapy for Advanced Non-Small-Cell Lung Cancer","volume":"26","author":"Chiappori","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1126\/science.1257216","article-title":"Alternative Lengthening of Telomeres Renders Cancer Cells Hypersensitive to ATR Inhibitors","volume":"347","author":"Flynn","year":"2015","journal-title":"Science"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"7488","DOI":"10.1038\/s41598-020-63294-z","article-title":"ATR Inhibition Broadly Sensitizes Soft-Tissue Sarcoma Cells to Chemotherapy Independent of Alternative Lengthening Telomere (ALT) Status","volume":"10","author":"Chaire","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3389\/fonc.2016.00186","article-title":"Cancer Cells with Alternative Lengthening of Telomeres Do Not Display a General Hypersensitivity to ATR Inhibition","volume":"6","author":"Deeg","year":"2016","journal-title":"Front. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/5\/938\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:04:58Z","timestamp":1760105098000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/5\/938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,26]]},"references-count":174,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["cancers16050938"],"URL":"https:\/\/doi.org\/10.3390\/cancers16050938","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,26]]}}}